StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.68−0.01 (-1.69%)

Close on Nov 16, 2026Market cap $25.69MP/E –Yield –

Metagenomi Therapeutics, Inc. saw revenue fall 51.8% to $25.21M over fiscal 2025. Free cash flow was -$85.80M. At the latest close the market valued the company at $25.69M.

Revenue
$25.21M
-51.8% vs. a year earlier
Operating income
-$100.57M
TTM Q2 2026
Free cash flow
-$85.80M
TTM Q2 2026
EPS, diluted
-$2.49
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026

Valuation

Market cap
$25.69M
P/E ratio
–
Price to sales
–
Price to book
0.23
Dividend yield
–
Free cash flow yield
-333.99%

Fundamentals

Revenue
$25.21M
Net income
-$93.46M
EPS, diluted
-$2.49
Free cash flow
-$85.80M
Book value per share
$2.99
Diluted shares
38M

Trading

Next earnings
Mar 4, 2027 (estimated, during market hours)
Previous close
$0.69
Open
$0.70
Day's range
$0.66 – $0.71
Volume
193,181
Average volume (20 days)
162,160
52-week range
$0.60 – $1.87
RSI (14 days)
32.3
Volatility (1 year)
52.7%
Relative volume
1.19×

Market cap history

Month-end market cap since 2024, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.

PeriodMGXS&P 500DifferenceMGX per yearS&P 500 per year
1 month-13.3%-3.1%−10.2 pts
3 months-44.7%-4.5%−40.3 pts
Year to date-58.0%+9.4%−67.4 pts
1 year-60.9%+11.3%−72.2 pts

Four years at a glance

Fiscal years 2022 to 2025 and trailing twelve months, USD

Revenue

–

Operating income

-$100.57M

Net income

-$93.46M

EPS, diluted

-$2.49

Free cash flow

-$85.80M
Reported periodTrailing twelve months

Press releases

Releases Metagenomi Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Metagenomi Therapeutics

Biological Products, (No Diagnostic Substances)

Metagenomi Therapeutics, Inc. is a genetic medicines company that develops next-generation genome editing systems to create curative therapies for patients. The company focuses on research and development efforts in genome editing using programmable nucleases, base editing, and RNA- and DNA-mediated integration systems, which include prime editors and CRISPR-associated transposases. It has not yet commercialized any product candidates and conducts research and development activities through strategic collaborations and license agreements with pharmaceutical partners such as Ionis and Moderna.

Company profile, executives and history

Metagenomi Therapeutics stock: common questions

What is Metagenomi Therapeutics's stock price?

MGX closed at $0.68 on Nov 16, 2026, down 1.69% on the day. Over the past 52 weeks it traded between $0.60 and $1.87.

What is Metagenomi Therapeutics's market cap?

Metagenomi Therapeutics was worth $25.69M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.

What is MGX's P/E ratio?

Metagenomi Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.49), so it has no meaningful P/E ratio.

How much revenue does Metagenomi Therapeutics make?

Metagenomi Therapeutics reported revenue of $25.21M for fiscal 2025, down 51.8% from a year earlier.

Does Metagenomi Therapeutics pay a dividend?

No. Metagenomi Therapeutics has not paid a cash dividend over the last twelve months.

When does Metagenomi Therapeutics report earnings next?

Metagenomi Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, during market hours. The date is estimated from its past reporting pattern until the company confirms it.

How has MGX stock performed over the past year?

Including dividends, MGX returned -60.9% over the past year, against +11.3% for the S&P 500.

How many MGX shares are sold short?

1M shares were sold short at the latest FINRA report, 3.93% of the float, or 11.1 days of average trading volume.

Who are Metagenomi Therapeutics's competitors?

Companies most similar to Metagenomi Therapeutics by business, industry and size include SGMOQ, EDIT, CRSP, RLAY, DTIL.

See a number that looks wrong?